Die Information für Ärzte und Apotheker
Neutral, unabhängig und anzeigenfrei
arznei-telegramm® 02/2017
previous issue next issue
This is a translation of the table of contents. One article is translated and freely available.

SPOT ON
Post-marketing trials without tangible benefit

NEW ON THE MARKET
Anti-interleukin-5 antibody reslizumab (CINQAERO) for severe eosinophilic asthma

THERAPY FROM A CRITICAL VIEWPOINT
Delirium in palliative care: neuroleptics worse than placebo
Tapentadol (PALEXIA, YANTIL): What

IN BRIEF
Migraine prevention in children: is placebo the best medicine?
Death following overdose of colchicine - the package size of the drop formulation is to be limited
France: zolpidem (STILNOX, generics) -narcotic prescription required
Glucosamine and chondroitin in osteoarthritis without benefit in yet another study

CURRENT ADR NETWORK REPORT
Urticaria with apixaban (ELIQUIS)

SIDE EFFECTS
Malformations with hydroxyethylrutoside (e.g. VENORUTON)?
Fatalities with selexipag (UPTRAVI) in pulmonary hypertension
Rivaroxaban (XARELTO): agranulocytosis and STEVENS-JOHNSON syndrome  free article 

e a-t ON THE INTERNET
Elbasvir plus Grazoprevir (ZEPATIER) for hepatitis C
Amputations with SGLT2 inhibitors
Once more: anaphylactic reactions with chlorhexidine
© 2020 arznei-telegramm